NCT06865222Recruiting
Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation
Variable Pulse Transcranial Magnetic Stimulation for Treatment of Post COVID Syndrome
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 25 Feb 2025
- Start date
- 22 Jul 2025
- Primary completion date
- Jan 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06865222
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 22 Jul 2025 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Implanted electronic devices, including pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators (VNS)
- Active alcohol abuse: \>14 drinks a week or formal diagnosis, illicit drug use or drug abuse
- Intracranial implant within 30 cm of magnet (e.g., aneurysm clips, endovascular coil, cerebral shunts, brain stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed
- Previous stroke with residual deficits
Other illness
- Any seizure history within the past 10 years
- Based on PI's or local physician's assessment that subject unable to tolerate the trial procedure due to medical condition
- Any condition which in the judgment of the investigator would prevent the subject from completion of the study
Lab values
- Clinical abnormality or clinically unstable medical condition, as indicated by medical history, physical examination, or clinical laboratory testing, that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results
Other
- Enrolled or plans to enroll in an interventional trial during this study
- Subjects unable to comprehend or follow verbal commands
- Subjects unable to comprehend and sign the informed consent
- Pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required for females of childbearing potential
Who the study is looking for
- Patients who have had a recent episode of COVID-19 and who present to the Post COVID-19 Clinic at Mayo Clinic Rochester with at least one of the PCC symptoms of interest - anosmia, tinnitus, fatigue. Symptoms consistent with PCC lasting at least 1 month after the positive test date. Subjects must have ongoing symptoms for \> 4 weeks following the start of an acute covid infection. This is consistent with the CDC definition for post covid conditions. Start date is determined by date of first positive COVID test. There is no limitation of maximum time from acute infection start.
- At least one of the PCC symptoms of interest:
- Anosmia: Olfactory Threshold Test scores corresponding to Anosmia or Hyposmia
- Tinnitus: \>0 score on Tinnitus Handicap Inventory (not present prior to SARS-COVID 2 infection)
- Fatigue: Total Modified Fatigue Impact Scale (MFIS) Score of 40 or above
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.